Involuntary movements caused by tardive dyskinesia (TD), a movement disorder induced by dopamine-receptor antagonists like ...

Teva Pharmaceuticals has a new game plan for raising awareness of tardive dyskinesia (TD). | Teva Pharmaceuticals has a new ...

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaignTD is a ...

Many people like to snack on peanut butter with apple slices for the vitamin E, but you have to be careful of other ...

In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their ...

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching 'The Other TD' campaignTD is a chronic movement disorder impacting one in four people who take certain pr ...

QOL Medical to Acquire All Outstanding Shares of Evoke for $11.00 Per Share in Cash Represents a 139.7% premium to most recent Nasdaq closing price Transaction expected to close by the end of 2025 ...

Continuous treatment with INGREZZA 40 mg for 48 weeks resulted in sustained, clinically meaningful improvements in tardive dyskinesia symptoms 90% of participants who completed 48 weeks of continuous ...

NEW ORLEANS - Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a biopharmaceutical company with a market capitalization of $13.64 billion and impressive revenue growth of 18.42% over the last twelve months ...

Both groups showed clinically meaningful improvements in tardive dyskinesia that were sustained throughout the 48-week treatment period. "The KINECT 4 post-hoc analysis demonstrated the rapid, ...

WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX), Friday announced a new post-hoc analysis from the Phase 3, open-label KINECT 4 study, evaluating the long-term efficacy, safety and ...